Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.36 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.36 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.36 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13269286 | 0.90 | ALDH1A1 (0.39) | KMT2AMEN1MAPTEGLN1ALDH1A1 | |
| SCHEMBL3179017 | 0.90 | MAPT (0.38) | GRIK1KMT2AMEN1MAPTEGLN1 | |
| SCHEMBL13269472 | 0.88 | ALDH1A1 (0.41) | KMT2AMEN1MAPTEGLN1ALDH1A1 | |
| SCHEMBL3200633 | 0.88 | MAPT (0.39) | KMT2AMEN1MAPTEGLN1ALDH1A1 | |
| SCHEMBL14899076 | 0.85 | MAPT (0.45) | KMT2AMEN1MAPTALDH1A1GAA | |
| SCHEMBL450892 | 0.84 | MAPT (0.39) | KMT2AMEN1MAPTEGLN1ALDH1A1 | |
| SCHEMBL14899078 | 0.83 | MAPT (0.46) | KMT2AMEN1MAPTEGLN1ALDH1A1 | |
| SCHEMBL2045397 | 0.80 | ALDH1A1 (0.42) | KMT2AMEN1MAPTEGLN1ALDH1A1 | |
| SCHEMBL9819391 | 0.77 | GRIK1 (0.36) | GRIK1GRIA1GRIA2GRIA4GRIK3 | |
| SCHEMBL15492519 | 0.77 | FAAH (0.51) | KMT2AMEN1MAPTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050250800-A1 | Conformationally constrained compounds as pharmaceutical agents | BRYANS JUSTIN S | 2005-11-10 | — | — | US | disclosed |
| EP-1311470-B1 | UNSATURATED ESTERS AND THEIR USE IN FRAGRANCE AND FLAVOUR COMPOSITIONS | GIVAUDAN SA (CH) | 2004-11-03 | — | — | EP | disclosed |
| US-20040023839-A1 | Unsaturated esters and their use in fragance and flavour compositions | GIVAUDAN SA (CH) | 2004-02-05 | — | — | US | disclosed |
| US-20030119858-A1 | Conformationally constrained compounds as pharmaceutical agents | BRYANS JUSTIN STEPHEN (GB) | 2003-06-26 | — | — | US | disclosed |
| EP-1311470-A1 | UNSATURATED ESTERS AND THEIR USE IN FRAGRANCE AND FLAVOUR COMPOSITIONS | Givaudan SA (CH) | 2003-05-21 | — | — | EP | disclosed |
| US-6489352-B2 | ANTIEPILEPTIC AGENTS; NERVOUS SYSTEM DISORDERS | WARNER-LAMBERT COMPANY | 2002-12-03 | — | — | US | disclosed |
| WO-2002016307-A1 | UNSATURATED ESTERS AND THEIR USE IN FRAGRANCE AND FLAVOUR COMPOSITIONS | GIVAUDAN SA (CH) | 2002-02-28 | — | — | WO | disclosed |
| EP-1182190-A1 | Unsaturated esters | Givaudan SA (CH) | 2002-02-27 | — | — | EP | disclosed |
| US-20020019540-A1 | Conformationally constrained compounds as pharmaceutical agents | BRYANS JUSTIN STEPHEN (GB) | 2002-02-14 | — | — | US | disclosed |
| US-6316638-B1 | FOR THERAPY OF EPILEPSY, FAINTNESS ATTACKS, HYPOKINESIA, CRANIAL DISORDERS, NEURODEGENERATIVE DISORDERS, DEPRESSION, ANXIETY, PANIC, PAIN, AND NEUROPATHOLOGICAL DISORDERS | WARNER-LAMBERT COMPANY | 2001-11-13 | — | — | US | disclosed |
| EP-1082306-A1 | CONFORMATIONALLY CONSTRAINED AMINO ACID COMPOUNDS HAVING AFFINITY FOR THE ALPHA2DELTA SUBUNIT OF A CALCIUM CHANNEL | WARNER-LAMBERT COMPANY (US) | 2001-03-14 | — | — | EP | disclosed |
| WO-1999061424-A1 | CONFORMATIONALLY CONSTRAINED AMINO ACID COMPOUNDS HAVING AFFINITY FOR THE ALPHA2DELTA SUBUNIT OF A CALCIUM CHANNEL | WARNER-LAMBERT COMPANY (US) | 1999-12-02 | — | — | WO | disclosed |
| EP-0358092-B1 | 2-AZA-4-(ALKOXYCARBONYL)SPIRO-(4,5)DECAN-3-ONE | LONZA A.G. (CH) | 1991-12-11 | — | — | EP | disclosed |
| US-4958044-A | 2-aza-4-(alkoxycarbonyl)spiro[4,5]-decan-3-one | LONZA LTD. (CH) | 1990-09-18 | — | — | US | disclosed |
| US-4956473-A | ANTICONVULSANTS | LONZA LTD. (CH) | 1990-09-11 | — | — | US | disclosed |
| EP-0358092-A1 | 2-Aza-4-(alkoxycarbonyl)spiro-(4,5)decan-3-one | LONZA A.G. (CH) | 1990-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250800-A1 | Conformationally constrained compounds as pharmaceutical agents | PYGB, GABRA6, GABRA2 | GRIK1 90/4885KMT2A 2184/4885MEN1 1848/4885 |
| US-20020019540-A1 | Conformationally constrained compounds as pharmaceutical agents | PYGB, SLC18A1, CDR2 | GRIK1 46/4885KMT2A 2225/4885MEN1 981/4885 |
| US-20040023839-A1 | Unsaturated esters and their use in fragance and flavour compositions | ELOVL5, FFAR3, ELOVL1 | GRIK1 76/4885KMT2A 4256/4885MEN1 4477/4885 |
| US-20030119858-A1 | Conformationally constrained compounds as pharmaceutical agents | PYGB, SLC18A1, CDR2 | GRIK1 46/4885KMT2A 2225/4885MEN1 981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.